Nanobiotix Sees Gains Following Initial Trial Results for Cancer Drug Developed in Partnership with J&J
Nanobiotix Phase 1 Trial Results: Nanobiotix's stock rose after announcing initial results from a Phase 1 trial of JNJ-1900 (NBTXR3), a cancer injection for solid tumors, showing an 85% disease control rate and a 69% objective response rate among 13 patients with esophageal cancer.
Study Progress and Safety Profile: The trial's findings included six complete remissions and three partial remissions, with a well-tolerated safety profile; enrollment for the study continues as the company seeks to recruit additional patients for further cohorts.
Trade with 70% Backtested Accuracy
Analyst Views on NBTX
About NBTX
About the author
Palvella Therapeutics Stock Soars to $114.69 Following Pipeline Developments
- Stock Performance: Palvella Therapeutics saw its stock surge from $25 on March 10, 2025, to a 52-week high of $114.69 on December 22, 2025, reflecting strong market potential in rare disease treatments.
- Product Development: Its lead product, QTORIN rapamycin, targets microcystic lymphatic malformations and other rare diseases, with potential FDA approval expected to unlock a multi-billion-dollar market opportunity, further solidifying the company's position in the biopharmaceutical sector.
- Acquisition Activity: Cidara Therapeutics agreed to be acquired by Merck for $221.50 per share, totaling approximately $9.2 billion, with the deal expected to close in Q1 2026, highlighting major pharmaceutical interest in innovative therapies.
- Clinical Progress: Celcuity's Gedatolisib submitted a New Drug Application to the FDA in November 2025 for HR+, HER2- advanced breast cancer, which, if approved, would significantly enhance its competitive edge in the oncology market.
Nanobiotix Reports Voting Rights and Share Capital Data
- Total Shares: As of November 30, 2025, Nanobiotix has 48,401,118 outstanding shares, indicating the company's stability and ongoing investment appeal in the market.
- Voting Rights Information: The total voting rights amount to 50,101,699, with theoretical voting rights at 50,079,581, ensuring shareholder participation in corporate decisions and reflecting the company's governance transparency.
- Market Position: Since its listing on Euronext Paris in 2012, Nanobiotix has consistently driven biotechnological innovation aimed at improving patient treatment outcomes, showcasing its leadership in the industry.
- Technology Platforms: The company owns over 25 patent families across oncology and central nervous system disorders, indicating a strong foundation in nanotechnology applications and future growth potential.
Shareholder Voting Rights and Company Capital Structure
Company Overview: Nanobiotix is a late-stage clinical biotechnology company based in Paris, specializing in innovative therapeutic approaches, particularly in oncology and central nervous system disorders, and is listed on Euronext Paris and Nasdaq.
Voting Rights Information: As of November 30, 2025, Nanobiotix has 48,401,118 shares outstanding, with a total of 50,101,699 theoretical voting rights and 50,079,581 exercisable voting rights.
Patents and Technology: The company holds over 25 patent families related to three nanotechnology platforms aimed at improving treatment outcomes for patients.
Contact Information: For inquiries, Nanobiotix provides contact details for its communications and investor relations departments, as well as media relations contacts in France and globally.
Nanobiotix Joins CAC Mid 60 and SBF 120 Indices, Enhancing Market Visibility
- Market Recognition: Nanobiotix will be included in the CAC Mid 60 and SBF 120 indices effective December 19, 2025, which not only enhances the company's visibility but also strengthens its presence in European equity markets.
- Investment Appeal: Inclusion in these indices is expected to attract more institutional investors, potentially leading to increased capital inflow that supports the company's innovative developments in cancer treatment.
- Strategic Confidence: CEO Laurent Levy stated that this admission reflects market confidence in the company's long-term strategy, highlighting the disruptive potential of its nanotherapeutic solutions.
- Future Outlook: As Nanobiotix advances toward key milestones, the company remains focused on disciplined execution and creating sustainable value to meet the needs of patients and partners.
Nanobiotix Joins CAC Mid 60 and SBF 120 Indices, Enhancing Market Visibility
- Market Recognition: Nanobiotix will officially join the CAC Mid 60 and SBF 120 indices on December 19, 2025, a move that not only enhances the company's market visibility but is also expected to attract more institutional investors, thereby strengthening its presence in European equity markets.
- Strategic Significance: CEO Laurent Levy stated that this inclusion reflects the financial markets' confidence in the company's long-term strategy, which is anticipated to drive innovation and development in physics-based medicine, ultimately creating sustainable value for patients and shareholders.
- Industry Impact: As a company focused on developing physics-based therapeutic approaches, Nanobiotix holds over 25 patents, and this index inclusion is expected to further expand its market share in oncology and central nervous system disorders.
- Future Outlook: With the company advancing towards key milestones, joining the CAC Mid 60 and SBF 120 indices will provide broader exposure to investment strategies, positioning it favorably within the rapidly evolving biotechnology sector.
Semtech Reports Mixed Q3 Results, Alongside Zhihu, Nvidia, and Other Major Stocks Declining in Tuesday's Pre-Market Trading
U.S. Stock Futures: U.S. stock futures are down, with Dow futures decreasing by approximately 0.1% on Tuesday morning.
Semtech Corp Financial Results: Semtech Corp's shares fell 7.2% in pre-market trading after reporting mixed third-quarter results, with revenue of $267 million missing estimates but adjusted earnings of 48 cents per share exceeding expectations.
Other Stocks Declining: Several other stocks also experienced declines in pre-market trading, including Arcus Biosciences (-6.7%), Nanobiotix (-6.2%), and Zhihu Inc (-5.2%).
Notable Stock Movements: Advanced Micro Devices and NVIDIA saw declines of 3.8% and 4.2%, respectively, following previous gains, indicating a broader trend of falling stock prices in the tech sector.
Palvella Therapeutics Stock Soars to $114.69 Following Pipeline Developments
- Stock Performance: Palvella Therapeutics saw its stock surge from $25 on March 10, 2025, to a 52-week high of $114.69 on December 22, 2025, reflecting strong market potential in rare disease treatments.
- Product Development: Its lead product, QTORIN rapamycin, targets microcystic lymphatic malformations and other rare diseases, with potential FDA approval expected to unlock a multi-billion-dollar market opportunity, further solidifying the company's position in the biopharmaceutical sector.
- Acquisition Activity: Cidara Therapeutics agreed to be acquired by Merck for $221.50 per share, totaling approximately $9.2 billion, with the deal expected to close in Q1 2026, highlighting major pharmaceutical interest in innovative therapies.
- Clinical Progress: Celcuity's Gedatolisib submitted a New Drug Application to the FDA in November 2025 for HR+, HER2- advanced breast cancer, which, if approved, would significantly enhance its competitive edge in the oncology market.
Nanobiotix Reports Voting Rights and Share Capital Data
- Total Shares: As of November 30, 2025, Nanobiotix has 48,401,118 outstanding shares, indicating the company's stability and ongoing investment appeal in the market.
- Voting Rights Information: The total voting rights amount to 50,101,699, with theoretical voting rights at 50,079,581, ensuring shareholder participation in corporate decisions and reflecting the company's governance transparency.
- Market Position: Since its listing on Euronext Paris in 2012, Nanobiotix has consistently driven biotechnological innovation aimed at improving patient treatment outcomes, showcasing its leadership in the industry.
- Technology Platforms: The company owns over 25 patent families across oncology and central nervous system disorders, indicating a strong foundation in nanotechnology applications and future growth potential.
Shareholder Voting Rights and Company Capital Structure
Company Overview: Nanobiotix is a late-stage clinical biotechnology company based in Paris, specializing in innovative therapeutic approaches, particularly in oncology and central nervous system disorders, and is listed on Euronext Paris and Nasdaq.
Voting Rights Information: As of November 30, 2025, Nanobiotix has 48,401,118 shares outstanding, with a total of 50,101,699 theoretical voting rights and 50,079,581 exercisable voting rights.
Patents and Technology: The company holds over 25 patent families related to three nanotechnology platforms aimed at improving treatment outcomes for patients.
Contact Information: For inquiries, Nanobiotix provides contact details for its communications and investor relations departments, as well as media relations contacts in France and globally.
Nanobiotix Joins CAC Mid 60 and SBF 120 Indices, Enhancing Market Visibility
- Market Recognition: Nanobiotix will be included in the CAC Mid 60 and SBF 120 indices effective December 19, 2025, which not only enhances the company's visibility but also strengthens its presence in European equity markets.
- Investment Appeal: Inclusion in these indices is expected to attract more institutional investors, potentially leading to increased capital inflow that supports the company's innovative developments in cancer treatment.
- Strategic Confidence: CEO Laurent Levy stated that this admission reflects market confidence in the company's long-term strategy, highlighting the disruptive potential of its nanotherapeutic solutions.
- Future Outlook: As Nanobiotix advances toward key milestones, the company remains focused on disciplined execution and creating sustainable value to meet the needs of patients and partners.
Nanobiotix Joins CAC Mid 60 and SBF 120 Indices, Enhancing Market Visibility
- Market Recognition: Nanobiotix will officially join the CAC Mid 60 and SBF 120 indices on December 19, 2025, a move that not only enhances the company's market visibility but is also expected to attract more institutional investors, thereby strengthening its presence in European equity markets.
- Strategic Significance: CEO Laurent Levy stated that this inclusion reflects the financial markets' confidence in the company's long-term strategy, which is anticipated to drive innovation and development in physics-based medicine, ultimately creating sustainable value for patients and shareholders.
- Industry Impact: As a company focused on developing physics-based therapeutic approaches, Nanobiotix holds over 25 patents, and this index inclusion is expected to further expand its market share in oncology and central nervous system disorders.
- Future Outlook: With the company advancing towards key milestones, joining the CAC Mid 60 and SBF 120 indices will provide broader exposure to investment strategies, positioning it favorably within the rapidly evolving biotechnology sector.
Semtech Reports Mixed Q3 Results, Alongside Zhihu, Nvidia, and Other Major Stocks Declining in Tuesday's Pre-Market Trading
U.S. Stock Futures: U.S. stock futures are down, with Dow futures decreasing by approximately 0.1% on Tuesday morning.
Semtech Corp Financial Results: Semtech Corp's shares fell 7.2% in pre-market trading after reporting mixed third-quarter results, with revenue of $267 million missing estimates but adjusted earnings of 48 cents per share exceeding expectations.
Other Stocks Declining: Several other stocks also experienced declines in pre-market trading, including Arcus Biosciences (-6.7%), Nanobiotix (-6.2%), and Zhihu Inc (-5.2%).
Notable Stock Movements: Advanced Micro Devices and NVIDIA saw declines of 3.8% and 4.2%, respectively, following previous gains, indicating a broader trend of falling stock prices in the tech sector.
